Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3682B in Chronic HCV GT1 or GT3 Infection
NCT02613403Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of grazoprevir, uprifosbuvir, ruzasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started Dec 2015; status: terminated.
02
Drugs
grazopreviruprifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02613403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613403.